<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384865</url>
  </required_header>
  <id_info>
    <org_study_id>458</org_study_id>
    <secondary_id>R01HL082895-01</secondary_id>
    <nct_id>NCT00384865</nct_id>
  </id_info>
  <brief_title>A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension</brief_title>
  <official_title>A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether aspirin and simvastatin are safe and
      effective for the treatment of pulmonary arterial hypertension (PAH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAH is characterized by dyspnea, fatigue, and lower extremity edema as a result of heart
      failure. In PAH, in situ thrombosis may occur in the lungs, and pulmonary endothelial
      dysfunction is well-recognized. As aspirin inhibits platelet aggregation, there may be value
      in using aspirin to treat PAH. Simvastatin has beneficial effects on blood vessels in other
      types of cardiovascular disease. Therefore, simvastatin may similarly benefit patients with
      PAH.

      Participants in this study will be randomly assigned to receive 6 months of daily placebo
      tablets, daily aspirin and daily placebo, daily simvastatin and daily placebo, or daily
      aspirin and daily simvastatin in a double-blind fashion. The study will compare the safety
      and efficacy of aspirin to placebo and simvastatin to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance Walked in Six Minutes</measure>
    <time_frame>Measured at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Worsening Events (Number of Events)</measure>
    <time_frame>Measured at 6 months</time_frame>
    <description>Defined by the addition of new PAH therapies or dose increases in previously stable PAH therapy, hospitalization for right-sided heart failure, lung transplantation, atrial septostomy, and cardiovascular and all-cause death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Measured at 6 months</time_frame>
    <description>Please refer to the Adverse Event Tables for specific information</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Aspirin 81 mg + Simvastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months
Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 81 mg + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months
Placebo taken orally, once a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Simvastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo taken orally, once a day for 6 months
Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken orally, once a day for 6 months
Placebo taken orally, once a day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 40 mg, taken orally, once a day for 6 months</description>
    <arm_group_label>Aspirin 81 mg + Simvastatin 40 mg</arm_group_label>
    <arm_group_label>Placebo + Simvastatin 40 mg</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 81 mg, taken orally, once a day for 6 months</description>
    <arm_group_label>Aspirin 81 mg + Simvastatin 40 mg</arm_group_label>
    <arm_group_label>Aspirin 81 mg + Placebo</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, taken orally, once a day for 6 months</description>
    <arm_group_label>Aspirin 81 mg + Placebo</arm_group_label>
    <arm_group_label>Placebo + Simvastatin 40 mg</arm_group_label>
    <arm_group_label>Placebo + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mean pulmonary artery pressure greater than 25 mm Hg at rest with a pulmonary
             capillary wedge pressure less than 16 mm Hg

          -  Diagnosis of PAH that is a) idiopathic, b) familial, or c) associated with collagen
             vascular disease, HIV infection, congenital systemic-to-pulmonary shunt, or former
             anorexigen use

          -  Most recent pulmonary function tests showing FEV1/FVC ratio greater than 50% AND one
             of the following conditions: a) total lung capacity greater than 70% predicted, or b)
             total lung capacity between 60% and 70% of predicted value with no more than mild
             patchy interstitial lung disease on high resolution computerized tomography of the
             chest

          -  Ability to perform six-minute walk testing without limitations in musculoskeletal
             function or coordination

          -  Negative pregnancy test at screening visit for women of childbearing potential

          -  If female, willing to use adequate form of birth control

        Exclusion Criteria:

          -  PAH related to other etiologies

          -  Diagnosis of sickle cell disease

          -  Clinically significant untreated sleep apnea, as diagnosed by polysomnography

          -  Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency
             or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection
             fraction less than 45% on echocardiography

          -  Hospitalized or acutely ill

          -  Kidney failure

          -  Initiation of PAH therapy (prostacyclin analogues, endothelin [ET]-1 receptor
             antagonists, phosphodiesterase [PDE]-5 inhibitors) within 3 months of study entry

          -  Allergy or hypersensitivity to aspirin or simvastatin

          -  Absolute indication for aspirin or other anti-platelet therapy

          -  Current treatment with statin therapy

          -  Inability or unwillingness to avoid non-steroidal, anti-inflammatory medications for 6
             months following study entry

          -  Current or recent use or planned treatment with one of the following: amiodarone,
             cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, HIV protease
             inhibitors, nefazodone, cimetidine, danazol, large quantities of grapefruit juice
             (more than 1 quart daily), verapamil, fibrates, or niacin

          -  Peptic or duodenal ulcer diagnosed within 1 year of study entry

          -  Gastrointestinal bleeding within 6 months prior of study entry

          -  Bleeding diathesis

          -  History of intracranial bleeding

          -  Anemia (hematocrit less than 30%) at screening

          -  International normalized ratio (INR) greater than 3.0 at screening

          -  Severe thrombocytopenia (less than 75,000/L) at screening

          -  Hepatic transaminases greater than twice the upper limit of normal at screening

          -  Chronic liver disease (e.g., cirrhosis, chronic hepatitis) with portal hypertension

          -  Current or recent (within 6 months of study entry) chronic heavy alcohol consumption

          -  History of myositis

          -  Creatine phosphokinase (CPK) greater than 1.5 times the upper limit of normal at
             screening

          -  Abnormalities of the arm or hand or past radical mastectomy that might prevent
             brachial artery ultrasound

          -  Pregnant or breastfeeding

          -  Current use of another investigational drug for PAH

          -  Received a lung transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Kawut, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David J Lederer, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reda E Girgis, MB, BCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kari E Roberts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, Tracy RP, Palevsky HI, Hassoun PM, Girgis RE; ASA-STAT Study Group. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation. 2011 Jun 28;123(25):2985-93. doi: 10.1161/CIRCULATIONAHA.110.015693. Epub 2011 May 18.</citation>
    <PMID>21593252</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <results_first_submitted>November 16, 2016</results_first_submitted>
  <results_first_submitted_qc>July 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2017</results_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aspirin 81 mg + Simvastatin 40 mg</title>
          <description>Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months
Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Aspirin 81 mg + Placebo</title>
          <description>Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months
Placebo: Placebo, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="P3">
          <title>Placebo + Simvastatin 40 mg</title>
          <description>Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months
Placebo: Placebo, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="P4">
          <title>Placebo + Placebo</title>
          <description>Placebo: Placebo, taken orally, once a day for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Six Month Assessment</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aspirin 81 mg + Simvastatin 40 mg</title>
          <description>Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months
Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Aspirin 81 mg + Placebo</title>
          <description>Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months
Placebo: Placebo, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Placebo + Simvastatin 40 mg</title>
          <description>Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months
Placebo: Placebo, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="B4">
          <title>Placebo + Placebo</title>
          <description>Placebo: Placebo, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="16.6"/>
                    <measurement group_id="B2" value="56.75" spread="13.2"/>
                    <measurement group_id="B3" value="58.6" spread="11.7"/>
                    <measurement group_id="B4" value="63.5" spread="14.2"/>
                    <measurement group_id="B5" value="59.6" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Distance Walked in Six Minutes</title>
        <time_frame>Measured at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin 81 mg</title>
            <description>Aspirin 81 mg, taken orally, once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Aspirin Placebo</title>
            <description>Placebo, taken orally, once a day for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatin 40 mg, taken orally, once a day for 6 months</description>
          </group>
          <group group_id="O4">
            <title>Simvastatin Placebo</title>
            <description>Placebo, taken orally, once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Distance Walked in Six Minutes</title>
          <units>meters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438.0" lower_limit="415.9" upper_limit="460.1"/>
                    <measurement group_id="O2" value="438.5" lower_limit="419.2" upper_limit="457.8"/>
                    <measurement group_id="O3" value="425.0" lower_limit="400.2" upper_limit="449.9"/>
                    <measurement group_id="O4" value="452.7" lower_limit="431.9" upper_limit="473.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clinical Worsening Events (Number of Events)</title>
        <description>Defined by the addition of new PAH therapies or dose increases in previously stable PAH therapy, hospitalization for right-sided heart failure, lung transplantation, atrial septostomy, and cardiovascular and all-cause death.</description>
        <time_frame>Measured at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin 81 mg</title>
            <description>Aspirin 81 mg, taken orally, once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Aspirin Placebo</title>
            <description>Placebo, taken orally, once a day for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatin 40 mg, taken orally, once a day for 6 months</description>
          </group>
          <group group_id="O4">
            <title>Simvastatin Placebo</title>
            <description>Placebo, taken orally, once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinical Worsening Events (Number of Events)</title>
          <description>Defined by the addition of new PAH therapies or dose increases in previously stable PAH therapy, hospitalization for right-sided heart failure, lung transplantation, atrial septostomy, and cardiovascular and all-cause death.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Please refer to the Adverse Event Tables for specific information</description>
        <time_frame>Measured at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin 81 mg</title>
            <description>Aspirin 81 mg, taken orally, once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Aspirin Placebo</title>
            <description>Placebo, taken orally, once a day for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin 40 mg</title>
            <description>Simvastatin 40 mg, taken orally, once a day for 6 months</description>
          </group>
          <group group_id="O4">
            <title>Simvastatin Placebo</title>
            <description>Placebo, taken orally, once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Please refer to the Adverse Event Tables for specific information</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for each subject from screening through 6 months after enrollment/randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aspirin 81 mg</title>
          <description>Aspirin 81 mg, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Aspirin Placebo</title>
          <description>Placebo, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="E3">
          <title>Simvastatin 40 mg</title>
          <description>Simvastatin 40 mg, taken orally, once a day for 6 months</description>
        </group>
        <group group_id="E4">
          <title>Simvastatin Placebo</title>
          <description>Placebo, taken orally, once a day for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Major Bleeding Episode</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Minor Bleeding Episode</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Transaminases</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other Infections</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary end point that should be used in early-stage clinical trials in PAH is uncertain.
We did not include invasive hemodynamic end points.
Early termination led to missing data for those active subjects in the trial at termination (n16).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven Kawut</name_or_title>
      <organization>Penn</organization>
      <phone>215-573-0258</phone>
      <email>kawut@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

